Lisdexamfetamine (Vyvanse)
Prodrug of d-amphetamine conjugated with L-lysine. Enzymatically cleaved in red blood cells to release active d-amphetamine, providing smooth onset and extended duration (~12-14 hours). Cannot be abused intranasally or IV as the prodrug is pharmacologically inactive, rate-limited by enzymatic hydrolysis. Used for ADHD and binge eating disorder. The PK values reflect the active d-amphetamine release profile.
Projected serum levels — 30 mg, once daily
Maintenance schedule: 30 mg once daily (oral).
Modeled steady state after ~1 days: peak ≈ 10.1 mg, trough ≈ 0.000 mg body load. Population-based estimate over 15 days for a 30 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Stimulant
- Route modeled
- Oral
- Model confidence
- inferred
- Half-life
- 10 h
- Common dose
- 30 mg
- Suggested maximum
- 70 mg/day
- Reference dose range
- 20–70 mg (single dose)
- Suggested cadence
- once daily
- Validated against
- 50 mg oral — Cmax 0.068 mg/L at 3.5 h
Documented interactions
-
danger
1P-LSD (1-Propionyl-LSD) + Lisdexamfetamine (Vyvanse)
1P-LSD (1-Propionyl-LSD) and Lisdexamfetamine (Vyvanse) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
-
danger
25I-NBOMe + Lisdexamfetamine (Vyvanse)
25I-NBOMe and Lisdexamfetamine (Vyvanse) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
-
danger
2C-I (2,5-Dimethoxy-4-iodophenethylamine) + Lisdexamfetamine (Vyvanse)
2C-I (2,5-Dimethoxy-4-iodophenethylamine) and Lisdexamfetamine (Vyvanse) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental…
-
danger
2C-B (4-Bromo-2,5-dimethoxyphenethylamine) + Lisdexamfetamine (Vyvanse)
2C-B (4-Bromo-2,5-dimethoxyphenethylamine) and Lisdexamfetamine (Vyvanse) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental…
-
danger
3-MeO-PCP (3-Methoxyphencyclidine) + Lisdexamfetamine (Vyvanse)
3-MeO-PCP (3-Methoxyphencyclidine) and Lisdexamfetamine (Vyvanse) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
-
danger
4-AcO-DMT (Psilacetin) + Lisdexamfetamine (Vyvanse)
4-AcO-DMT (Psilacetin) and Lisdexamfetamine (Vyvanse) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
Serum checks 136 modeled interaction pairings for lisdexamfetamine (vyvanse) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.
Research behind this entry
-
Lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: a 13-hour simulated workplace crossover study
Simulated workplace RCT demonstrating lisdexamfetamine maintained significant ADHD symptom improvement for 13+ hours post-dose versus placebo, with smooth onset and sustained efficacy throughout the day.
-
Pharmacokinetic profile of lisdexamfetamine dimesylate: relationship to d-amphetamine exposure
Pivotal PK study establishing lisdexamfetamine's prodrug conversion kinetics: d-amphetamine tmax of 3.5 hours, half-life of 10-12 hours, dose-proportional exposure, and reduced Cmax variability versus immediate-release…
-
Lisdexamfetamine dimesylate for the treatment of binge eating disorder: a randomized, double-blind, placebo-controlled trial
Phase III RCT establishing lisdexamfetamine 50-70 mg/day as effective for binge eating disorder, reducing binge days per week from 4.5 to 0.8 versus 2.3 with placebo.
3 published studies referenced in the app, each with a plain-language summary.